about
Tumor-related epilepsy and epilepsy surgery.Seizure prognosis in brain tumors: new insights and evidence-based managementCortical GABAergic excitation contributes to epileptic activities around human glioma.Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapyNetwork Plasticity and Intraoperative Mapping for Personalized Multimodal Management of Diffuse Low-Grade Gliomas.Seizure management in patients with gliomas.Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.Extracellular electrical recording of pH-triggered bursts in C6 glioma cell populations.Epileptic seizure in primary intracranial sarcoma: a case report and literature review.Brain tumors in eloquent areas: A European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis.Epileptic seizures in anaplastic gangliogliomas.Compromised GABAergic inhibition contributes to tumor-associated epilepsy.Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis.Identifying clinical risk in low grade gliomas and appropriate treatment strategies, with special emphasis on the role of surgery.Activation of the mTOR signaling pathway in peritumoral tissues can cause glioma-associated seizures.In Vivo Tumour Mapping Using Electrocorticography Alterations During Awake Brain Surgery: A Pilot Study.Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study.Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival
P2860
Q30712949-37386B06-3951-4C66-B32B-497E2D9590AFQ33829789-FB5D0117-9D3A-4EBB-95F2-85C063564C6FQ35535883-B20A5CBC-55E7-44FA-B13A-D69C6D0FBDF2Q36893208-9DC557E0-845E-4B2B-A4D4-560E4F48ED25Q37614559-D96D4EFC-AC8E-4730-83E7-7AE918381217Q38189495-9F26A802-F240-4602-8D14-18C6C8F9BE65Q38495389-A10B8814-292E-4E27-9B99-543ABFA70DE1Q38724034-35189D98-F6C6-4B4C-8406-F656988FBEA1Q38895783-DD96AA32-5ECF-4DC7-B766-6FF90115CFA0Q39535596-7FDD33FA-C09B-4EA9-910E-9CB92F9ECEECQ40611722-36177ECE-59CB-4450-936E-DCF64EE3AEAAQ41640926-A46ACEF2-10F0-459F-B5B4-52188B9FCF5EQ41685604-421F6C17-BE5A-4B26-B17F-13767F42982FQ47558551-D78725ED-A8F7-4554-841C-01BA6EF960C1Q48504763-7CD9F175-7BE6-400D-B691-FCAF34D8FFE1Q48665223-E89ECA47-DFD8-421D-AC91-FF14AEBBDF35Q52568033-E175E097-EEB0-4401-8BC9-52E60B72BFFBQ57296293-00E18336-B017-49C9-BA54-A4204BDFF905
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tumoral epileptogenicity: how does it happen?
@en
type
label
Tumoral epileptogenicity: how does it happen?
@en
prefLabel
Tumoral epileptogenicity: how does it happen?
@en
P2093
P2860
P356
P1433
P1476
Tumoral epileptogenicity: how does it happen?
@en
P2093
Gilles Huberfeld
Johan Pallud
Laurent Capelle
P2860
P356
10.1111/EPI.12440
P478
54 Suppl 9
P577
2013-12-01T00:00:00Z